Implications of Physical Access Barriers for Breast Cancer Diagnosis and Treatment in Women With Mobility Disability

2021 ◽  
pp. 104420732110101
Author(s):  
Nicole D. Agaronnik ◽  
Areej El-Jawahri ◽  
Lisa I. Iezzoni

More than 30 years since enactment of the Americans with Disabilities Act, people with disability continue to face physical access barriers, notably inaccessible medical diagnostic equipment, in clinical settings. Access barriers affect breast cancer screening and treatment for women with disability. We used standard diagnosis codes and natural language processing to screen electronic health records (EHRs) in a digital data repository from a large health care delivery system for patients with pre-existing mobility disability diagnosed with breast cancer between 2005 and 2017. We reviewed EHRs of 20 patients, using conventional content analysis to examine breast cancer diagnosis and treatment experiences. Clinicians noted challenges positioning patients for routine procedures including manual breast exam, screening mammography, and breast biopsies. Given challenges accommodating disability for adjuvant therapies, mastectomy was favored over breast-conserving options despite early stages of diagnosis. Notations contained little information about proactive problem-solving for arranging accommodations. Notations described physical access barriers for breast cancer detection and treatment, with limited planning for mitigating barriers. Despite 2017 promulgation of federal Standards for Accessible Medical Diagnostic Equipment, implementing these standards requires further rulemaking.

2010 ◽  
Vol 62 (2) ◽  
pp. 150-165 ◽  
Author(s):  
Miriam Colombo ◽  
Fabio Corsi ◽  
Diego Foschi ◽  
Elisa Mazzantini ◽  
Serena Mazzucchelli ◽  
...  

2009 ◽  
Vol 121 (3) ◽  
pp. 743-751 ◽  
Author(s):  
Elena M. Kouri ◽  
Yulei He ◽  
Eric P. Winer ◽  
Nancy L. Keating

2013 ◽  
Vol 80 (1) ◽  
pp. 94-98 ◽  
Author(s):  
Michael B. Altman ◽  
Michael J. Flynn ◽  
Robert M. Nishikawa ◽  
Indrin J. Chetty ◽  
Kenneth N. Barton ◽  
...  

Pathobiology ◽  
2011 ◽  
Vol 78 (2) ◽  
pp. 99-114 ◽  
Author(s):  
Anthony S.-Y. Leong ◽  
Zhengping Zhuang

2000 ◽  
Vol 24 (5) ◽  
pp. 515-519 ◽  
Author(s):  
Celia McMichael ◽  
Maureen Kirk ◽  
Lenore Manderson ◽  
Elizabeth Hoban ◽  
Helen Potts

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 12003-12003 ◽  
Author(s):  
Andrew M. Wardley ◽  
David Ryder ◽  
Vivek Misra ◽  
Peter S Hall ◽  
Peter Mackereth ◽  
...  

12003 Background: CIPN is a dose limiting toxicity, and a major clinical challenge. This study aims to explore the use of acupuncture with standard care (Acu +SC) against SC alone, to reduce symptoms of CIPN. Methods: A phase II, randomised, parallel group design was used to investigate the effectiveness of a 10 week course of acupuncture to manage CIPN. Patients experiencing CIPN ≥ Grade II (CTCAE v4.03), recording a ‘Most Troublesome’ CIPN symptom score of ≥ 3 using the "Measure Yourself Medical Outcome Profile" (MYMOP 2), were randomised (1:1) to either Acu+SC or SC alone. The primary end-point was a ≥ 2 point improvement in MYMOP2 score at week 10 (logistic regression adjusted for stratification factors and baseline MYMOP2 score). The necessary sample size was 100 patients;120 were randomised to allow for attrition (90% power; 10% one-sided alpha), for a hypothesised improvement in success proportions from 30% to 55%. Results: 120 patients were randomised to ACUFOCIN; diagnosis: breast 61 (51%), multiple myeloma 9 (8%), GI 48 (40%), gynaecological 2 (2%). MYMOP2 score for most troubling CIPN symptom at baseline: 3-4 33 (28%), 5-6 87 (73%). CTCAE CIPN at baseline; grade II 103 (86%), grade III 17 (14%). Baseline characteristics were balanced between arms. Primary outcome data were available for 108 participants with 36/54 (67%) successes in the Acu+SC arm compared to 18/55 (33%) in the SC arm. Adjusted success odds ratio was 4.3 (95% CI 1.9-9.6; p < 0.001; Acu+SC vs SC). Additionally, 27/53 (51%) participants achieved a CIPN success (grade ≤ I) in the Acu+SC arm compared to 4/56 (7%) in the SC arm with adjusted odds ratio 13.1 (95% CI 4.1-41.7; p < 0.001; Acu+SC vs SC). Significant reduction in week 10 pain score; mean difference (SC+Acu – SC alone) -1.45 with 95% CI (-2.25, -0.65) after adjustment for week 1 pain, breast cancer diagnosis and treatment complete status. (note pain on a 0-10 scale). Significant increase in the EORTC QLQ-C30 summary score; mean difference (SC+Acu – SC alone) 9.51 with 95% CI (5.01, 14.02) after adjustment for the baseline score, breast cancer diagnosis and treatment complete status. (note summary score on a 0-100 scale). Significant effects seen at week 10 are also present at week 6. The week 6 effect estimates are consistently less than the week 10 effects (but not usually statistically significantly so). Conclusions: In this patient cohort, a 10 week course of acupuncture significantly improved symptoms of CIPN. These results support further investigation within a phase III trial. Clinical trial information: NCT02275403 .


2008 ◽  
Vol 116 (3) ◽  
pp. 609-616 ◽  
Author(s):  
Eunmi Ahn ◽  
Juhee Cho ◽  
Dong Wook Shin ◽  
Byeong Woo Park ◽  
Sei Hyun Ahn ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document